Trade Sarepta Therapeutics, Inc. - SRPT CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.23 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 61.56 |
| Open | 61.75 |
| 1-Year Change | -51.89% |
| Day's Range | 61.75 - 63.86 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 61.56 | -2.65 | -4.13% | 64.21 | 65.45 | 61.26 |
| Mar 31, 2025 | 63.18 | -2.47 | -3.76% | 65.65 | 66.95 | 62.25 |
| Mar 28, 2025 | 69.92 | -1.00 | -1.41% | 70.92 | 71.86 | 69.54 |
| Mar 27, 2025 | 71.33 | -0.72 | -1.00% | 72.05 | 73.43 | 71.20 |
| Mar 26, 2025 | 72.43 | -1.23 | -1.67% | 73.66 | 73.66 | 70.67 |
| Mar 25, 2025 | 73.13 | -2.95 | -3.88% | 76.08 | 76.08 | 71.93 |
| Mar 24, 2025 | 75.84 | 1.59 | 2.14% | 74.25 | 76.45 | 74.25 |
| Mar 21, 2025 | 73.98 | 1.17 | 1.61% | 72.81 | 75.09 | 72.70 |
| Mar 20, 2025 | 73.31 | -5.21 | -6.64% | 78.52 | 79.79 | 73.01 |
| Mar 19, 2025 | 79.86 | 4.91 | 6.55% | 74.95 | 80.70 | 74.95 |
| Mar 18, 2025 | 73.47 | -5.63 | -7.12% | 79.10 | 81.42 | 72.95 |
| Mar 17, 2025 | 100.93 | 3.98 | 4.11% | 96.95 | 102.96 | 96.95 |
| Mar 14, 2025 | 96.96 | -1.49 | -1.51% | 98.45 | 99.64 | 96.92 |
| Mar 13, 2025 | 97.68 | -1.44 | -1.45% | 99.12 | 99.96 | 97.10 |
| Mar 12, 2025 | 99.18 | -1.88 | -1.86% | 101.06 | 101.78 | 98.96 |
| Mar 11, 2025 | 100.56 | 1.66 | 1.68% | 98.90 | 101.38 | 97.83 |
| Mar 10, 2025 | 99.16 | -2.78 | -2.73% | 101.94 | 101.94 | 98.76 |
| Mar 7, 2025 | 102.86 | -0.73 | -0.70% | 103.59 | 104.68 | 101.72 |
| Mar 6, 2025 | 105.29 | -0.49 | -0.46% | 105.78 | 107.04 | 103.98 |
| Mar 5, 2025 | 107.46 | 4.71 | 4.58% | 102.75 | 107.69 | 102.75 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Sarepta Company profile
Sarepta Therapeutics, Inc. focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin. It also provides Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations that are amenable to exon 53 skipping; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene. In addition, the company provides SRP-5051, a peptide conjugated PMO that binds to exon 51 of dystrophin pre-mRNA resulting in exclusion of exon during mRNA processing in patients with genetic mutations that are amenable to exon 51 skipping. The company has strategic alliances with Nationwide Children's Hospital for the advancement of micro-dystrophin gene therapy program under the research and license option agreement, as well as Galgt2 gene therapy program under the license agreement; and Genethon for the advancement of micro-dystrophin gene therapy program under a research and exclusive license option agreement. It also has a research and license option agreement with Duke University for the advancement of gene editing CRISPR/Cas9 technology for muscular dystrophy; and a collaboration and license agreement with Summit (Oxford) Ltd. to commercialize products in Summit's utrophin modulator pipeline. The company distributes its products through a network of specialty distributors and specialty pharmacies in the United States, as well as through distributors internationally. Sarepta Therapeutics, Inc. was founded in 1980 and is headquartered in Cambridge, Massachusetts.| Industry: | Bio Therapeutic Drugs |
215 1st St Ste 415
CAMBRIDGE
MASSACHUSETTS 02142-1213
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com